Stanislav Ignatenko
Berlin, BE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Olamkicept up to 2400 mg in Healthy Men: Phase I, Randomized, Placebo-Controlled, and Double-Blind Trial.
Journal: Clinical and translational science
Published: February 06, 2026
B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment.
Journal: Annals of the rheumatic diseases
Published: July 15, 2025
The Effect of Various Degrees of Renal or Hepatic Impairment on the Pharmacokinetic Properties of Once-Weekly Insulin Icodec.
Journal: Clinical pharmacokinetics
Published: February 13, 2024
A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis.
Journal: Clinical and translational medicine
Published: July 31, 2023
Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial.
Journal: Diabetes, obesity & metabolism
Published: April 19, 2021
Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects.
Journal: Pulmonary pharmacology & therapeutics
Published: March 28, 2020
Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.
Journal: Clinical pharmacokinetics
Published: December 22, 2018
Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults.
Journal: European journal of endocrinology
Published: March 05, 2018
Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus.
Journal: Lupus
Published: July 11, 2017
Safety, PK, and PD of recombinant anti-interleukin-21 monoclonal antibody in a first-in-human trial.
Safety, PK, and PD of recombinant anti-interleukin-21 monoclonal antibody in a first-in-human trial.
Journal: International journal of clinical pharmacology and therapeutics
Published: February 03, 2016
Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme.
Journal: The New England journal of medicine
Published: May 19, 2015
Showing 1-12 of 12
Last Updated: 09/26/2026